The recommended insulin dose starts to increase after this threshold and surpasses the clinician doses when glucose levels were above 200 mg/dL, demonstrating a proactive approach to correcting significant hyperglycemia aligning with the recommendations to avoid hyperglycemia while minimizing the risk of hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.